Valeant Pharmaceuticals International Inc (NYSE:VRX)(TSX:VRX) stated on Thursday that it plans to pay down another USD200m of its senior secured term loans with cash on hand.
Following the repayment of debt next week, the company will have reduced its debt, in aggregate, by more than USD6.7bn since the end of Q1 2016.
In conjunction, the company's total long-term debt will be about USD25.5bn.
The specialist pharmaceutical company develops, manufactures and markets a broad range of pharmaceutical products in dermatology, gastrointestinal disorders, eye health, neurology and branded generics.
Par Health launches generic version of Janumet XR tablets in US
EQL Pharma gains approval to sell Mellozzan in Kazakhstan
Newbury Pharmaceuticals receives Swedish approval for generic tofacitinib
Breckenridge launches Tofacitinib Tablets, generic equivalent to Pfizer's Xeljanz
Hims & Hers expands GLP-1 offering in Canada with generic semaglutide
Apotex announces commercial launch of Apo-Semaglutide Injection in Canada
Transpire Bio's generic high-strength Trelegy Ellipta ANDA accepted for filing by US FDA
Kaiser Permanente reports study findings showing significant cost savings
Apotex receives Health Canada approval for a generic Ozempic equivalent
Cipla's AB-rated Ventolin HFA generic receives US FDA approval
Newbury Pharmaceuticals secures first Scandinavian approval for palbociclib generic
Apotex's generic Ozempic (Semaglutide Injection) receives US FDA tentative approval
DifGen and Apotex report FDA approval of generic Nintedanib Soft Gel Capsules